EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry

Lisa P van der Rijst iD, Karin M de Winter-de Groot, Nicolaas P A Zuithoff, Marjolein S de Bruin-Weller, Marlies de Graaf

Pediatric Allergy and Immunology · 2024

DOI: 10.1111/pai.14178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2024. Verfasst von Lisa P van der Rijst und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht University, Utrecht, The Nether…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Asthma, Antibodies, Monoclonal, Humanized, Immunoglobulin E. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) is frequently associated with asthma and allergic rhinitis (AR). Dupilumab is an effective treatment for pediatric AD, although the effect on atopic comorbidities in pediatric AD patients is limited.

Objective

To investigate the prevalence of asthma and AR in pediatric AD patients starting dupilumab treatment and to evaluate the effect of dupilumab on these comorbidities.

Methods

This study included pediatric AD patients (aged 3–17 years) treated with dupilumab between 2019 and 2023. Patients were screened at baseline by a pulmonologist for the presence of asthma and AR. Screening included evaluation of medical history and current symptoms, spirometry (including Forced Expiratory Volume in 1 s (FEV 1 )), Fractional exhaled Nitric Oxide (FeNO), and measurement of aeroallergen‐specific IgE levels. In patients diagnosed with comorbid asthma and/or AR, measurements were repeated at weeks 16 and 52. Spirometry measurements, FeNO, and aeroallergen‐specific IgE levels during treatment were analyzed using a covariance pattern model.

Results

Eighty‐four patients were included. Asthma was diagnosed in 50 patients (59.5%) and AR in 72 patients (85.7%). Baseline FeNO levels were elevated in both patients with (29.0 ppb (95% CI 22.0–54.0)) and without asthma (26.0 ppb (95% CI 22.0–30.0)). During treatment, FeNO levels decreased ( p < .001) and FEV 1 scores increased ( p < .001) in patients with asthma. In patients with asthma and/or AR, all aeroallergen‐specific IgE levels decreased between 61.3% and 89.1% at 52 weeks of treatment.

Conclusion

One year of dupilumab treatment, primarily indicated for AD, resulted in a significant improvement in comorbid asthma and a profound decrease in aeroallergen‐specific IgE levels in patients with asthma and/or AR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAsthmaAntibodies, Monoclonal, HumanizedImmunoglobulin EAllergensRegistriesHumansChildFemaleMaleAdolescentChild, PreschoolRhinitis, AllergicPrevalenceSpirometryTreatment OutcomeComorbidityNitric Oxide

Stichwörter der Autor:innen

Dupilumaballergic rhinitisasthmaatopic dermatitisatopychildrentype 2 inflammation

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedImmunoglobulin EAllergensNitric Oxide

Autor:innen und Institutionen

  • Department of Dermatology and Allergology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht University, Utrecht, The Netherlands.
  • Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Department of Pediatric Pulmonology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht University, Utrecht, The Netherlands.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID-Profile: Lisa P van der Rijst

Zitieren

APA

van der Rijst, L. P., de Winter-de Groot, K. M., Zuithoff, N. P. A., de Bruin-Weller, M. S., & de Graaf, M. (2024). Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.14178

Vancouver

van der Rijst LP, de Winter-de Groot KM, Zuithoff NPA, de Bruin-Weller MS, de Graaf M. Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry. Pediatric Allergy and Immunology. 2024. doi:10.1111/pai.14178

BibTeX
@article{vanderRijst2024,
  author = {van der Rijst, Lisa P and de Winter-de Groot, Karin M and Zuithoff, Nicolaas P A and de Bruin-Weller, Marjolein S and de Graaf, Marlies},
  title = {Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry},
  journal = {Pediatric Allergy and Immunology},
  year = {2024},
  doi = {10.1111/pai.14178}
}
Kostenlos starten →